The FDA recently granted priority review to a new drug application for melflufen (INN melphalan flufenamide), in combination with dexamethasone. Melflufen is intended for use as a first choice for patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody (triple-class refractory). 

Melflufen is a peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. The combination treatment demonstrated encouraging efficacy and a manageable safety profile in heavily pretreated patients. The myeloma panel is taking a deep dive on  melflufen with Dr. Paul G. Richardson from Dana Farber Cancer Institute and will touch upon the details of the trials, side effects and treatment regimen.